You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Currently, only approximately 20% of cancers respond to existing immuno-oncology treatments. Through Primary Focus (PF) Immuno-Oncology, we dedicate our collective strengths to find new ways to treat and ultimately cure patients with cancer. By reprogramming the body’s innate and adaptive immune systems, we aim to reinvigorate its ability to discover, disarm and destroy different types of cancer cells.
We combine our strong heritage in oncology, leading expertise, and innovative teams with like-minded partners to create value through new, transformative treatments for the majority of patients who do not respond to currently available immuno-oncology therapies.
Our three-step strategic approach “Focus, Enrich, and Expand” guides our innovation approach and investments, and accelerates our progress towards the discovery and development of the next-generation of immuno-oncology therapies.
We Focus on advancing novel modalities that target multiple pathways across the cancer-immunity cycle with first- or best-in-class potential that could fundamentally transform outcomes for patients. We Enrich our pipeline by enhancing our skills and capabilities through collaboration, both internally with teams across Astellas where we can synergize expertise, and externally by partnering with some of the brightest minds in biotechnology and academia. We continually seek to Expand our modality platforms into adjacent tumor types and disease areas where we can best leverage our existing strengths , enhancing our ability to translate innovative science into meaningful value for patients.
Our Immuno-Oncology (IO) pipeline spans multiple modalities, including antibody-based approaches such as antibody drug conjugates (ADC’s) and bispecific antibodies, as well as small molecules and cell therapy.
Astellas’ Flagship IO program is ASP2138, a potential first-in-class treatment for people with stomach cancer, gastroesophageal junction cancer (GEJ cancer) or pancreatic cancer. ASP2138 is a bispecific immune cell engager designed to bind to CLDN18.2 (a protein that is expressed on certain tumor cells) and a type of white blood cell known as a CD3-positive T cell. By binding to both of these targets simultaneously, ASP2138 is designed to bring these T cells closer to CLDN18.2-expressing tumor cells and activate their anti-tumor action.
Please view our pipeline for Immuno-Oncology below. You can also access the full Astellas pipeline page here.
For everyone in the cancer community, the ultimate goal is cure, but no one scientist, company or organization can cure cancer alone. It requires spirited collaboration, a commitment to open exchange of expertise and bold exploration. With the shared aim of revolutionizing outcomes for patients with cancer, we have invested in a series of networked innovation hubs and are working with renowned academic institutions and industry partners from around the world to accelerate the specialized platform-based aspects of our strategy.
To learn more about how to collaborate with Astellas, please visit our Partnering page.
Astellas strives to match the best science and the best talent in order to deliver on our mission to turn innovative science into VALUE for patients. We encourage you to visit our Careers page to learn how you can join our work to turn innovative science into VALUE for patients.
